News
-
Receptor Life Sciences has raised $29 million for development of several cannabinoid products, the company said. In 2016, MannKind Corporation announced that it had licensed its dry powder inhalation technology to Receptor, which was then… Read more . . .
-
Inhaler testing equipment company Copley Scientific has announced the official opening of its newly expanded headquarters in Nottingham, UK. The company announced the project, which nearly doubled the size of the existing building, in February… Read more . . .
-
Glenmark Pharmaceuticals has officially opened its first US manufacturing site in Monroe, North Carolina, the company said. The 100,000 sq ft, $100 million facility will eventually produce hundreds of millions of doses in various forms… Read more . . .
-
Royal Philips has announced the launch of the InnoSpire Go hand-held vibrating mesh nebulizer system in the US. InnoSpire Go is already available in the UK, Australia, Denmark, Finland, Germany, and Norway. Philips acquired the… Read more . . .
-
Belgian soft mist inhaler company Softhale has announced the appointment of Nevan Charles Elam to its board of directors. Currently Chairman and CEO of Rezolute, Elam was formerly Senior VP and Head of the Pulmonary… Read more . . .
-
According to the Scottish government, a new manufacturing facility built by GSK in Montrose to produce APIs for its Ellipta dry powder inhalers officially opened on October 22, 2018, with Scottish First Minister Nicola Sturgeon… Read more . . .
-
Cambridge Design Partnership (CDP) has announced the appointment of OINDP device designer David Harris to head up the company’s respiratory drug delivery development business. According to CDP, the company is entering “a new phase of… Read more . . .
-
Perrigo said that Adapt Pharma and Opiant Pharmaceuticals have initiated patent litigation in the United States District Court for the District of New Jersey in regards to Perrigo’s recently filed ANDA for a generic version… Read more . . .
-
Galecto Biotech announced that it raised €79 million in a series C financing round that will be used to fund a Phase 2/3 study of its TD139, an inhaled galectin-3 inhibitor, for the treatment of… Read more . . .
-
VistaGen Therapeutics said that it has exercised an option to acquire an exclusive worldwide license for Pherin Pharmaceutical’s PH10 intranasal steroid, which is in Phase 2 development for the treatment of major depressive disorder (MDD).… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.